SS Innovations International, Inc.
SS Innovations International, Inc., situated in Fort Lauderdale, Florida, focuses on the development of sophisticated robotic systems for surgical use. Their offerings encompass the SSI Mantra, a specialized surgical robot, and SSI Mudra, a suite of surgical instruments designed to facilitate various operations,…
1D
-1.9%
1W
-4.5%
1M
-22.6%
6M
-48.3%
YTD
-55.5%
1Y
-70.9%
2Y
-33.4%
5Y
–
10Y
–
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~26% weaker price swings than usual
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$7.00
No current analyst ratings available.
P/E
-38.8
P/B
9.48
EV/EBITDA
-80.05
RETURN ON EQUITY
-5.0%
NET MARGIN
-19.1%
DEBT/EQUITY
0.06
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
3.9%
FLOAT SHARES
7,743,262
AVG. DAILY VOLUME (30D)
67,514
Sudhir Srivastava
Sudhir Srivastava
Sudhir Srivastava
Vishwajyoti Pascual Srivastava
Sudhir Srivastava
SS Innovations International, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Sudhir Prem Srivastava, the company employs around 483 people.
The IPO was on 17/10/2018; the stock trades on NASDAQ under the ticker SSII.
The average price target is US$7.00, ranging from US$7.00 to US$7.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -26% stronger than usual.
No, SS Innovations International currently does not pay a dividend.
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
Clicking "Analyze stock" lets five strategies assess SS Innovations International against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.